Systemic immunotherapy with immune checkpoint inhibitors is here to shake up the long-standing stagnant water in the treatment of bladder cancer, both in BCG-resistant high grade TCC and as an neoadjunctive therapy in muscle-invasive cancer. But what happens in the case of non-invasive urothelial cancer? The internationally renowned Greek Oncologist presents us the new therapeutic landscape in most cases of bladder cancer.
UroSecrets II: What has changed in the Treatment of Urolethelial Cancer
16:30 - 17:30